Working… Menu

Comparison of Barium Enema, Computed Tomographic Colonography, and Colonoscopy in Detecting Colon Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00016029
Recruitment Status : Terminated
First Posted : January 27, 2003
Last Update Posted : March 22, 2013
Information provided by (Responsible Party):
Duke University

Brief Summary:

RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for cancer. New diagnostic procedures such as computed tomographic colonography may provide a less invasive method of identifying patients who have colon cancer.

PURPOSE: Diagnostic and screening trial to compare the effectiveness of barium enema, computed tomographic colonography, and colonoscopy in detecting of colon cancer.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Other: screening questionnaire administration Procedure: barium enema injection Procedure: computed tomography Procedure: computed tomography colonography Procedure: diagnostic colonoscopy Procedure: screening colonoscopy Not Applicable

Detailed Description:


  • Compare the accuracy of air contrast barium enema, computed tomographic colonography (virtual colonoscopy), and colonoscopy for the detection of colonic lesions in patients with factors related to colon cancer.
  • Compare the patient experience during each of these imaging tests.

OUTLINE: This is a multicenter study.

A repeat fecal occult blood test is performed. Patients then undergo an air contrast barium enema (ACBE). At 7-10 days after ACBE, patients undergo a computed tomographic colonography (virtual colonoscopy) followed by a colonoscopy on the same day.

A repeat ACBE may be performed if there is a discrepancy between the initial ACBE and colonoscopy. If the repeat ACBE continues to show an abnormality, patients undergo a second colonoscopy.

Within 24 hours of completion of each test, patients fill out a questionnaire about their experience. At 5-7 days after completion of all tests, patients complete a final questionnaire comparing all 3 tests.

PROJECTED ACCRUAL: A total of 2,133 patients will be accrued for this study within 4 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 775 participants
Primary Purpose: Diagnostic
Official Title: Prospective Comparison of Air Contrast Barium Enema (ACBE), Computed Tomographic Colonography (Virtual Colonoscopy) and Colonoscopy for Evaluation of the Colon in Patients With Fecal Occult Blood
Study Start Date : August 2000
Actual Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Colonoscopy
Drug Information available for: Barium

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • One of the following must be present:

    • At least 1 positive fecal occult blood test within the past 6 months
    • Iron deficiency anemia, defined as:

      • Hemoglobin less than 13 g/dL (males)
      • Hemoglobin less than 12 g/dL (females)
      • Ferritin less than 45 g/dL
    • Episode of bright red blood per the rectum
    • Family history of colon cancer or adenoma

      • One first-degree relative diagnosed with colon cancer or adenoma at age 60 or under OR
      • Two first-degree relatives diagnosed with colon cancer or adenoma at any age
  • No active gastrointestinal hemorrhage, including any of the following:

    • Reported or witnessed hematemesis
    • Melenic stools
    • Melenemesis
    • Multiple episodes of hematochezia within the past 2 months



  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • See Disease Characteristics


  • Not specified


  • Not specified


  • No myocardial infarction or cerebrovascular accident within the past 6 weeks


  • No respiratory failure within the past 6 weeks


  • No serious medical disorder (e.g., sepsis) within the past 6 weeks
  • Weight less than 300 pounds
  • Willing and able to undergo endoscopic or radiologic procedures

    • No need for special precautions in performing endoscopic procedures (e.g., antibiotic prophylaxis or complicated anticoagulation reversal)
  • No prisoners
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified


  • No other concurrent clinical trial participation involving drugs, medical devices, and/or biologics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00016029

Layout table for location information
United States, California
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, United States, 92093-0658
California Pacific Medical Center - Pacific Campus
San Francisco, California, United States, 94115
California Pacific Medical Center - California Campus
San Francisco, California, United States, 94118-1618
Veterans Affairs Medical Center - San Francisco
San Francisco, California, United States, 94121
United States, Florida
Indian River Radiology
Vero Beach, Florida, United States, 32960
United States, Illinois
University of Chicago Cancer Research Center
Chicago, Illinois, United States, 60637-1470
United States, Michigan
Troy Internal Medicine, P.C.
Troy, Michigan, United States, 48098
United States, New Jersey
Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
United States, New York
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York, New York, United States, 10016
United States, North Carolina
Veterans Affairs Medical Center - Durham
Durham, North Carolina, United States, 27705
Duke Comprehensive Cancer Center
Durham, North Carolina, United States, 27710
United States, Texas
Simmons Cancer Center - Dallas
Dallas, Texas, United States, 75235-9154
University of Texas Medical Branch
Galveston, Texas, United States, 77555
United States, Virginia
Massey Cancer Center
Richmond, Virginia, United States, 23298-0037
Sponsors and Collaborators
Duke University
Layout table for investigator information
Study Chair: Don Rockey, MD Duke Cancer Institute

Additional Information:
Layout table for additonal information
Responsible Party: Duke University Identifier: NCT00016029     History of Changes
Other Study ID Numbers: 0866
CDR0000068587 ( Other Identifier: NCI )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: March 22, 2013
Last Verified: September 2003
Keywords provided by Duke University:
colon cancer
rectal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases